This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Regimen for tricylic antidepressants in neuropathic pain

Authoring team

Treatment should be commenced at a low dose:

  • with respect to neuropathic pain:
    • offer oral amitriptyline or pregabalin as first-line treatment
    • for amitriptyline
      • start at 10 mg per day, with gradual upward titration to an effective dose or the person's maximum tolerated dose of no higher than 75 mg per day (higher doses could be considered in consultation with a specialist pain service)

Based on both the early and regular clinical reviews:

  • if there is satisfactory improvement, continue the treatment; consider gradually reducing the dose over time if improvement is sustained
  • if amitriptyline* as first-line treatment results in satisfactory pain reduction but the person cannot tolerate the adverse effects, consider oral imipramine* or nortriptyline* as an alternative
    • * in these recommendations, drug names are marked with an asterisk if they do not have UK marketing authorisation for the indication in question at the time of publication of NICE guidance (March 2010). Informed consent should be obtained and documented

The summary of product characteristics must be consulted before prescribing the drug mentioned.

Reference:

  1. BNF 4.7.3
  2. NICE (March 2010). Neuropathic pain (adults) - pharmacological management

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.